SAINT-LAURENT, CANADA--(Marketwired - Aug. 2, 2016) - IntelGenx Technologies Corp., (TSX
VENTURE:IGX)(OTCQX:IGXT), today announced that it will release its second quarter 2016 results for the period ended June 30,
2016, on August 11, 2016 at the close of the financial markets.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer and Mr. Andre
Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the
conference call and webcast are below:
Date: Thursday, August 11, 2016
Time: 4:30 p.m. ET
Conference dial-in: (877) 201-0168
Conference ID: 47950179
International dial-in: (647) 788-4901
Webcast Registration: Click Here
Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".
About IntelGenx:
IntelGenx is a leading drug delivery company focused on the development of innovative products based on its proprietary oral
drug delivery technologies.
Established in 2003, the Montreal-based company, listed on the TSX-V and OTC-QX, develops innovative oral drug delivery
solutions based on its proprietary platform technologies, VersaFilm™, VersaTab™ and AdVersa™.
IntelGenx has developed a broad and diverse product portfolio addressing unmet market needs and offering lifecycle
management opportunities. Forfivo XL™, launched in 2012, is the first and only FDA approved once-daily bupropion HCl 450mg dose
in a single tablet for the treatment of major depressive disorder.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D,
clinical monitoring, IP protection, analytical method development and regulatory services. IntelGenx state-of-the art
manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale
production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.